Indoco Remedies Limited announced its outcome of the Board Meeting held on July 28, 2026, approving the unaudited standalone and consolidated financial results for the first quarter ended June 30, 2026. On a consolidated basis, the company reported revenue from operations of ₹467.50 Crores in Q1 FY27, representing a slight QoQ decrease of 1.71% (₹8.11 Crores) compared to ₹475.61 Crores in Q4 FY26, but a YoY increase of 6.33% (₹27.83 Crores) from ₹439.67 Crores recorded in Q1 FY26. On the profitability front, Indoco Remedies achieved a remarkable turnaround by registering a consolidated net profit of ₹65.44 Crores in Q1 FY27. This reflects a massive QoQ increase of ₹89.12 Crores (+376.35%) from a net loss of ₹23.68 Crores in Q4 FY26, and a YoY growth of ₹101.79 Crores (+280.03%) compared to a net loss of ₹36.35 Crores in Q1 FY26, boosted significantly by an exceptional gain of ₹97.34 Crores from the slump sale of its Ophthalmic Business Division.

Indoco Remedies Limited is a fully integrated, research-oriented global pharmaceutical company engaged in the manufacturing and marketing of finished dosage formulations (FDFs) and active pharmaceutical ingredients (APIs) across diverse therapeutic segments including gastrointestinal, respiratory, anti-infectives, stomatologicals, and pain management. The company operates 10 state-of-the-art manufacturing facilities approved by major global regulatory agencies, including the USFDA and UK-MHRA, servicing both Indian domestic markets and overseas generic partnerships.